Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

BACKGROUND: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. METHODS: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T-C-A) or camrelizumab and apatinib alone (C-A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety. RESULTS: A total of 252 HCC patients were included (T-C-A group, n = 183; C-A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group (24.2 months [95% CI: 21.4-33.4] vs. 15.2 months [95% CI: 9.8-21.0]; p < 0.001). The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group (p < 0.001). Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and 14.5% in the C-A group. CONCLUSION: The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2026-03-31
DOI
https://doi.org/10.1111/apt.70612
Citations
1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
15.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

Zhenggang Ren, Jin‐Feng Bai, Bin‐Yan Zhong, Fanpu Ji et al.
1 citations
Alimentary Pharmacology & Therapeutics
Hepatocellular Carcinoma Treatment and Prognosis
15.88
article

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

Zhenggang Ren, Jin‐Feng Bai, Bin‐Yan Zhong, Fanpu Ji, Jian‐Jian Chen, Meng-Lin Huang, Hai‐Dong Zhu, Aibing Xu, Yao Xiao, Ming‐Sheng Huang, W. B. Yang, G. Teng, Z. Jin, Kang‐Shun Zhu, Rui‐Bao Liu, Hai‐Bin Shi, Bao‐Qi Shi, Yu‐Jing Xin, Jun Tie, Lan Zhang, Qiang Tu, Jian‐Song Ji, Guo‐Hui Xu, Jin‐Zhang Chen, Chun‐Wang Yuan, Xiao‐Li Zhu, Rong Ding
article en
1 citations

Abstract

BACKGROUND: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. METHODS: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T-C-A) or camrelizumab and apatinib alone (C-A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety. RESULTS: A total of 252 HCC patients were included (T-C-A group, n = 183; C-A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group (24.2 months [95% CI: 21.4-33.4] vs. 15.2 months [95% CI: 9.8-21.0]; p < 0.001). The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group (p < 0.001). Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and 14.5% in the C-A group. CONCLUSION: The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).

Alimentary Pharmacology & Therapeutics
Fujian Medical University (CN), Ministry of Education of the People's Republic of China (CN), Central South University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), Fudan University (CN), Kunming Medical University (CN), Lishui University (CN), Soochow University (CN), National Clinical Research Center for Digestive Diseases (CN), Second Affiliated Hospital of Guangzhou Medical University (CN), Jiangxi Provincial Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Nanfang Hospital (CN), Nantong Tumor Hospital (CN), Zhongda Hospital Southeast University (CN), Shandong Provincial Hospital (CN), Sichuan Cancer Hospital (CN), Inner Mongolia People's Hospital (CN), Zhongshan Hospital (CN), Second Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of China Medical University (CN), Third Affiliated Hospital of Sun Yat-sen University (CN), Beijing YouAn Hospital (CN), Jiangsu Province Hospital (CN), First Affiliated Hospital of Soochow University (CN), Second Xiangya Hospital of Central South University (CN), Xijing Hospital (CN), Shandong First Medical University (CN), Union Hospital (CN), Hangzhou Cancer Hospital (CN), Southern Medical University (CN), Nanjing Medical University (CN), Xi'an Jiaotong University (CN), China Medical University (CN), Guangzhou Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province, National Key Research and Development Program of China
Good health and well-being
Openalex Percentile: Top 1%
Hepatocellular Carcinoma Treatment and Prognosis
15.88
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.